Bradycardia in a pediatric population after sugammadex administration: case series

Abstract Sugammadex is a distinctive neuromuscular reversal drug that acts by encapsulating the neuromuscular relaxant molecule and dislodging it from its site of action. Sugammadex has been approved for pediatric patients over 2 years of age. Although arrhythmias have been reported, there is no rep...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian Journal of Anesthesiology 2023-01, Vol.73 (1), p.101-103
Main Authors: Carvalho, Erica Viviana Guimarães, Caldas, Sandra Maria Carvalho, Costa, Dinis Fernando Pereira Pinheiro Machado da, Gomes, Cristina Maria Graça Peixoto
Format: Article
Language:Portuguese
Subjects:
ANESTHESIOLOGY
MEDICINE, GENERAL & INTERNAL
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Sugammadex is a distinctive neuromuscular reversal drug that acts by encapsulating the neuromuscular relaxant molecule and dislodging it from its site of action. Sugammadex has been approved for pediatric patients over 2 years of age. Although arrhythmias have been reported, there is no report of adverse effects in healthy children, such as severe bradycardia requiring intervention. We report two cases of severe bradycardia immediately after the administration of sugammadex in healthy children. Our aim is to alert to the occurrence of one of the most severe adverse effects of sugammadex, in the healthy pediatric population as well.
ISSN:2352-2291
DOI:10.1016/j.bjane.2021.12.011